Opinion

Video

Selecting Optimal Treatment in BCG-Unresponsive NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
      Expert discusses the NMIBC trials landscape
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Related Content
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      May 9th 2025

      Durvalumab plus BCG significantly improves DFS in NMIBC

      Benjamin P. Saylor Hannah Clarke
      The data are to be presented at an upcoming medical conference.
      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
      May 26th 2022

      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

      Urology Times staff
      “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
      FDA to host advisory committee meeting on UGN-102 for NMIBC
      May 7th 2025

      FDA to host advisory committee meeting on UGN-102 for NMIBC

      Hannah Clarke
      The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.
      FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
      May 5th 2025

      FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

      Hannah Clarke
      The sBLA for NAI was submitted to the FDA in March 2025.
      © 2025 MJH Life Sciences

      All rights reserved.